All In Biotech

Drug Trial Radar · NCT00004802

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders

Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

64

Actual

Start

Jun 1992

Primary completion

Not stated

Sponsor

Sponsor type
NIH
Collaborators
Ohio State University
First posted
Feb 25, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 10 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.

Conditions

  • Paralysis, Hyperkalemic Periodic
  • Hypokalemic Periodic Paralysis
  • Paramyotonia Congenita

Interventions

  • dichlorphenamideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.